Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds Cell Therapeutics' ovarian cancer (CaO) drug Xyotax has the potential to be the first modified taxane to be launched in major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Xyotax is the only modified taxane to have reached Phase III development for CaO, making it most likely to achieve first-to-market status in this indication. However, according to the new Pharmacor study entitled Ovarian Cancer, the modified taxane pipeline is burgeoning with candidates including agents by Bristol-Myers Squibb and American Pharm Partners.
"Clinicians we spoke to for this study predict that modified versions of existing classes of cytotoxics (most notably, taxanes), such as Xyotax and agents from Bristol-Myers Squibb and American Pharm Partners, will experience rapid uptake assuming that Phase III trials demonstrate improved toxicity profiles and efficacy that is at least equivalent to current therapies," said Mary Fletcher-Louis, analyst at Decision Resources.
Disease Facts-Ovarian Cancer
CaO is usually caught late in many patients -- at which point, it has often metastasized to other parts of the body. It is often too late for any drug therapies to be truly effective. Among patients diagnosed with late-stage disease -- 75% of first diagnoses are with late-stage disease -- five-year survival stands at only 25%.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Ovarian Cancer is an Onkos study.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/